Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10424222 | 0.80 | MEN1 (0.35) | MEN1KMT2A | |
| SCHEMBL28558998 | 0.79 | TSHR (0.36) | — | |
| SCHEMBL5059056 | 0.79 | HCAR2 (0.37) | — | |
| SCHEMBL7623067 | 0.77 | MEN1 (0.33) | MEN1KMT2A | |
| SCHEMBL7625114 | 0.77 | MEN1 (0.33) | MEN1KMT2A | |
| SCHEMBL5057254 | 0.76 | ALDH1A1 (0.48) | — | |
| SCHEMBL27647806 | 0.76 | THRB (0.50) | — | |
| SCHEMBL16830100 | 0.74 | GLO1 (0.45) | MEN1KMT2A | |
| SCHEMBL5050851 | 0.73 | TSHR (0.54) | — | |
| Diamidophosphate SCHEMBL28198667 | 0.73 | THRB (0.43) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110475784-A | It is used to prepare the three-dimensional orthogonal protecting group for limiting phosphorothioate oligonucleotide | ROCHE INNOVATION CT COPENHAGEN AS | 2019-11-19 | — | — | CN | disclosed |
| CN-106459969-B | Compositions and methods for modulating growth hormone receptor expression | IONIS制药公司 | 2019-11-15 | — | — | CN | disclosed |
| CN-106232804-B | Compositions and methods for modulating complement factor B expression | IONIS制药公司 | 2019-10-25 | — | — | CN | disclosed |
| CN-110079524-A | For adjusting the composition and method of HBV and TTR expression | IONIS制药公司 | 2019-08-02 | — | — | CN | disclosed |
| CN-110066795-A | For adjusting the composition and method of HBV and TTR expression | IONIS制药公司 | 2019-07-30 | — | — | CN | disclosed |
| CN-110042098-A | For adjusting the composition and method of HBV and TTR expression | IONIS制药公司 | 2019-07-23 | — | — | CN | disclosed |
| CN-105378085-B | Compositions and methods for modulating HBV and TTR expression | IONIS制药公司 | 2019-02-15 | — | — | CN | disclosed |
| CN-108064162-A | Conjugated antisense compounds and uses thereof | IONIS制药公司 | 2018-05-22 | — | — | CN | disclosed |
| CN-106459969-A | Compositions and methods for modulating growth hormone receptor expression | IONIS制药公司 | 2017-02-22 | — | — | CN | disclosed |
| CN-106255755-A | Compositions and methods for modulating angiopoietin-like protein 3 expression | IONIS制药公司 | 2016-12-21 | — | — | CN | disclosed |
| CN-106232125-A | Compositions and methods for modulating PKK expression | IONIS制药公司 | 2016-12-14 | — | — | CN | disclosed |
| CN-106232804-A | Compositions and methods for modulating complement factor B expression | IONIS制药公司 | 2016-12-14 | — | — | CN | disclosed |
| CN-103702994-B | The phosphoric acid ester of gyrase and topoisomerase enzyme inhibitor | VERTEX PHARMACEUTICALS INC. (US) | 2016-03-23 | — | — | CN | disclosed |
| CN-105392488-A | Compositions and methods for modulating apolipoprotein c-iii expression | ISIS PHARMACEUTICALS INC | 2016-03-09 | — | — | CN | disclosed |
| CN-105378085-A | Compositions and methods for modulating HBV and TTR expression | ISIS PHARMACEUTICALS INC | 2016-03-02 | — | — | CN | disclosed |
| CN-105378082-A | Compositions and methods | ISIS PHARMACEUTICALS INC | 2016-03-02 | — | — | CN | disclosed |
| CN-105377887-A | Compositions and methods for modulating apolipoprotein (a) expression | ISIS PHARMACEUTICALS INC | 2016-03-02 | — | — | CN | disclosed |